Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 19/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 11/20 | 1.00 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.62 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.62 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidofludimus SCHEMBL29869156 | 0.85 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL3919682 | 0.84 | DHODH (0.73) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL29868614 | 0.84 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL248265 | 0.82 | DHODH (0.76) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| Vidofludimus SCHEMBL29868416 | 0.81 | DHODH (0.85) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL249112 | 0.80 | DHODH (1.00) | DHODHNR4A2 | |
| SCHEMBL3990108 | 0.80 | DHODH (0.73) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL3924512 | 0.80 | DHODH (0.72) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL3926504 | 0.78 | DHODH (0.79) | DHODHNR4A2 | |
| SCHEMBL3924899 | 0.78 | DHODH (0.65) | DHODHNR4A2JMJD7NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130879-A1 | VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS | IMMUNIC AG (DE) | 2026-05-14 | — | — | US | disclosed |
| US-20240335405-A1 | VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS | IMMUNIC AG (DE) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130879-A1 | VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS | NR0B1, NR4A1, NR4A2 | DHODH 15/4885NR4A2 3/4885JMJD7 3532/4885 |
| US-20240335405-A1 | VIDOFLUDIMUS AND RELATED STRUCTURES ACTING AS NURR1 AGONISTS | NR4A1, NR4A2, NR0B1 | DHODH 2057/4885NR4A2 2/4885JMJD7 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.